Independent risk factors for COVID-19-associated coagulopathy.

Publication date: Aug 01, 2023

Past three years since the beginning of the outbreak, we have obtained satisfactory data on COVID-19. However, data on risk factors of COVID-19-associated coagulopathy (CAC) are extremely limited. Prediction of CAC might be a game changer since it is related to poor prognosis. Seeking independent risk factors for CAC was the main aim of the study. 510 hospitalized COVID-19 patients were retrospectively screened. Forty-eight of them were excluded due to irrelevant D-dimer or ferritin elevation. The remaining patients were stratified into three groups as overt coagulopathy, significant pulmonary microthrombosis, and patients without coagulopathy. The overt coagulopathy group included cases with macrothrombosis or disseminated intravascular coagulation (DIC). The significant pulmonary microthrombosis group covered the cases that had clinical deterioration with simultaneous marked D-dimer elevation. The group of patients without coagulopathy included the asymptomatic patients with normal or elevated D-dimer levels. Overt coagulopathy developed in 3. 2% and significant pulmonary microthrombosis in 10. 1% of the patients. In the multivariate analysis, not receiving low molecular weight heparin (LMWH) (p=0. 002), a level of D-dimer >15,000 U/ml (p=0. 013) were associated with overt coagulopathy. In addition, levels of initial LDH >480 IU/L (p=0. 022) and initial ferritin >1,000 ng/ml (p=0. 036) were associated with significant pulmonary microthrombosis. Not receiving LMWH (p=0. 001) was also associated with significant pulmonary microthrombosis, when multivariate analysis was performed by the parameters with a p-value

Concepts Keywords
Coagulopathy Bacteremia
Molecular Blood Coagulation Disorders
Poor COVID-19
Heparin, Low-Molecular-Weight
Heparin, Low-Molecular-Weight
Retrospective Studies
Risk Factors


Type Source Name
disease MESH COVID-19
disease MESH disseminated intravascular coagulation
drug DRUGBANK Dacarbazine
drug DRUGBANK Heparin
disease MESH Bacteremia
disease MESH Blood Coagulation Disorders

Original Article

(Visited 1 times, 1 visits today)